Columvi, Linzess, Recell, Bylvay, Eroxon
Manage episode 407556919 series 3561458
Get our free download! Implementing AMA Style – 8 Things to Get Right
In this episode, we discuss the latest FDA approvals from June 12 – June 16, 2023. Here are the key highlights:
· The FDA has granted accelerated approval to Roche's Columvi® (glofitamab) for the treatment of DLBCL and large B-cell lymphoma.
· Linzess® (linaclotide) capsules have been approved by the FDA to treat functional constipation in pediatric patients aged 6 to 17 years.
· The FDA has granted premarket approval to the RECELL® autologous cell harvesting device for the treatment of vitiligo, a skin condition characterized by depigmentation.
· Bylvay® (odevixibat) has received FDA approval for the treatment of cholestatic pruritus in patients with Alagille syndrome.
· The FDA has approved Eroxon®, a topical gel, as an over-the-counter treatment for erectile dysfunction.
If you need medical writing assistance please visit Nascent Medical. Nascent Medical specialize in high-quality medical writing services and they are available on call to meet your deadlines. Nascentmc.com
Intro and outro music
54 episodes